PPARG and type 2 diabetes mellitus: Despite their efficacy in T2D, PPARγ agonists such as thiazolidinediones (TZDs) cause adverse effects like weight gain by stimulating lipogenic gene expression, including AP2, CD36, SCD-1, and SREBP-1.496